During dual antiplatelet therapy, Cangrelor or eptifibatide, etc., short-acting parental antithrombotics may be considered in the first three months of post percutaneous coronary intervention as compared to aspirin and oral P2Y12...
Most Recent Articles
Hemodynamic Trial Study to Show Riociguat Outcomes In Patients of Heart Failure With Pulmonary Hypertension and Preserved Ejection Fraction
The DYNAMIC trial study was a randomized, multicenter, placebo-controlled, double-blind IIB trial between 5 hospitals across Germany and Austria. A sample of 58 patients for riociguat and 56 for placebo therapy was selected. The...
Trial to Study Comprehensive Lifestyle Intervention for Cardiovascular Disease Prognosis and Prevention
Eligible asymptomatic individuals between the age range 40-50 years from the progression of early sub-clinical atherosclerosis cohort were selected through stratified randomization sample techniques in Spain. Stratification was...
VISUALIZED: Trial Study to Show Empagliflozin Outcomes In Patients of Chronic Heart Failure and Reduced Ejection Fraction—EMPEROR-Reduced
Read further: Trial Study to Show Empagliflozin Outcomes In Patients of Chronic Heart Failure and Reduced Ejection Fraction—EMPEROR-Reduced
Trial Study to Show Empagliflozin Outcomes In Patients of Chronic Heart Failure and Reduced Ejection Fraction—EMPEROR-Reduced
This study was carried out to check the efficacy of empagliflozin in heart failure patients. For this purpose sample of 1863 patients for empagliflozin dosage and 1867 for placebo treatment was randomized. Inclusion criteria were...